Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06849622 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

Study acronym: CELDI
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis. This is a pilot study on screening of autoantibodies of type 1 diabetes and celiac disease in tuscany patients. The study aims to evaluate the concordance between the screening results obtained using two different matrix (blood drop spots on card and serum) in the search for autoantibodies for celiac disease and for type 1 diabetes. Moreover, it will be evaluated the feasibility and acceptability of the screening on a sample of the population enrolled in the territory through the participation of pediatricians.
Trial Details
NCT Number NCT06849622
Lead Sponsor Meyer Children's Hospital IRCCS
Conditions
(from sponsor)		 Celiac Disease in Children, Diabetes Mellitus, Type I, Screening
Related terms Diabetes Mellitus, Type 1
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov